TriSalus prices $40M public offering of 9.76M shares at $4.10/share

TriSalus Life Sciences, Inc.

Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).
Underwriters granted 30-day option to purchase up to 1,463,415 additional shares (15% of offering).
Offering expected to close February 23, 2026; Lake Street Capital Markets sole book-runner.
Net proceeds estimated at ~$42.64M if over-allotment fully exercised.
Proceeds for general corporate purposes including working capital and G&A.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.